Over-looked by many here: GC re-iterates a reverse
Post# of 30028
"Of greatest note in this preliminary proxy statement is the fact that the Company has not put forth a request for a reverse split of the common shares. Many of you are likely asking how the Company can possibly expect to up-list to a national exchange in 2014 without the need for a reverse split of its common shares. The answer is that the Company does not know where its common shares will be priced towards the end of this year, and therefore cannot project what will be required in terms of a reverse split or if a reverse split will be needed. However, we remain optimistic that we can significantly increase shareholder value through value building events both from a scientific and clinical perspective, as well as a capital markets perspective:"
See more at: http://www.thechairmansblog.com/amarantus-bio...RozbP.dpuf